<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957086</url>
  </required_header>
  <id_info>
    <org_study_id>IHN01</org_study_id>
    <nct_id>NCT00957086</nct_id>
  </id_info>
  <brief_title>Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head &amp; Neck Cancer</brief_title>
  <official_title>Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head &amp; Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to improve the loco-regional control rate and overall survival of
      locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that
      the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both
      epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold
      standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after
      resection of their locally advanced HNSCC will confer therapeutic advantage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to improve the loco-regional control rate and overall survival of
      locally advanced head and neck squamous carcinoma (HNSCC). We hypothesize that the addition
      of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal
      growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of
      concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection
      of their locally advanced HNSCC will confer therapeutic advantage. We have designed a phase
      III randomized study that includes a placebo arm. We assume a 10% increase in 2 year disease
      free survival (from 60% to 70%). To achieve statistical significance at 90% power, we
      calculate the need for 355 patients per arm, assuming also a 10% dropout rate. We aim to
      accomplish this study with the involvement of a multidisciplinary team of surgical, radiation
      and medical oncologists actively involved in the management of HNSCC coming from multiple
      institutions and spanning at least 12 different countries. For quality assurance we will have
      the involvement of Singapore Clinical Research Institute who will lead the data coordination
      and ensure fidelity of data collected and statistical analysis; the European Society of
      Therapeutic Radiation Oncology (EQUAL-ESTRO) for radiation dose and fields and an
      international independent panel of medical oncologist, radiation oncologist and
      biostatistician for the Data Monitoring Committee (DMC). This committee will monitor
      significant events and advise on continuation or termination of trial. Concurrent with the
      randomized trial, we will be collecting bio specimens including blood, tumour and saliva,
      pre-treatment and on completion of surgical resections. We hypothesize that there are
      important biomarkers including clusters of genes, cancer stem cells that will predict
      prognosis and treatment response. The analyses performed will be very powerful because of the
      large sample size, the specimens are collected prospectively and because the statistical
      analyses will be multivariate, incorporating not only treatment but biological and staging
      data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the overall survival between the two arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the Toxicity Profile between the 2 arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">710</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comprising Adjuvant Cisplatin, Concurrent RT and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.</description>
    <arm_group_label>Nimotuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age should be greater than or equal to the minimum age of consent in the applicable
             country

          -  Histologically proven head and neck squamous cell cancer (excluding nasopharynx,
             salivary glands, paranasal sinuses and unknown primaries) on biopsy of the primary
             lesion or the neck mass.

          -  Resectable stage III/IV according to the AJCC/UICC staging system with no evidence of
             distant metastasis.

          -  Complete macroscopic resection.

          -  Patients should have at least one of the following pathological features for
             inclusion: pT3 or pT4 and any nodal stage (N), except T3N0 of the larynx, with
             negative resection margins, or a tumor stage of 1 or 2 with a nodal stage of 2 or 3
             and no distant metastasis (M0); patients with stage T1 or T2 and N0 or N1 who had
             unfavorable pathological findings (extranodal spread, positive resection margins,
             perineural involvement, or vascular tumor embolism) are also eligible, as are those
             with oral-cavity or oropharyngeal tumors with involved lymph nodes at level IV or V.

          -  Performance status must be ECOG 0 or 1. Patients should be able to tolerate
             chemotherapy and radiotherapy.

          -  Adequate bone marrow, renal and hepatic function:

               1. WBC&gt;3000/mm3, platelets&gt;100000/mm3

               2. Serum creatinine&lt;upper limit of normal range as per institution and calculated
                  creatinine clearance (according to the Cockcroft and Gault method) &gt;50 ml/min.

               3. SAP, SGOT&lt;2 x upper limit of normal range, bilirubin &lt;1.5 x upper limit of normal
                  range.

          -  Written informed consent.

        Exclusion Criteria:

          -  Histology other than SCC or its subtype.

          -  Patients with disease subsite deemed suitable for organ preservation approach, namely
             stage III/IV laryngeal or hypopharyngeal carcinoma with not more than low-volume T4
             disease; low-volume T4 disease is defined as disease not eroding into cartilage or
             extending not more than 1 cm into the base of tongue.

          -  Clinical or radiological evidence of distant metastasis.

          -  Uncontrolled comorbidities such as diabetes mellitis, hypertension, cardiac disease.

          -  Uncontrolled infection.

          -  Uncontrolled hypercalcemia.

          -  Prior history of cancer less than 5 years ago or a synchronous primary outside the
             head and neck area.

          -  Prior treatment, head and neck radiotherapy, chemotherapy or surgery (excluding
             biopsy) or anti-EGFR therapy such as cetuximab/EGFR oral tyrosine kinase inhibitor.

          -  Patients for whom compliance with follow-up is unlikely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K C Soo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>K C Soo, Prof</last_name>
    <phone>+65 64368000</phone>
    <email>admskc@nccs.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>E H Tan, Dr</last_name>
    <phone>+65 64368000</phone>
    <email>dmoteh@nccs.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawgi Sukumaran</last_name>
      <email>Shawgi.Sukumaran@health.sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Weaver</last_name>
      <email>catherine.weaver@health.sa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Shawgi Sukumaran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>VIC 3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology and Radiobiology</name>
      <address>
        <city>Vedado</city>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelido Gonzalez Fernandez</last_name>
      <phone>537 8382590</phone>
      <email>nelido@infomed.sld.cu</email>
    </contact>
    <contact_backup>
      <last_name>Jenny Avila</last_name>
      <phone>537 8382590</phone>
      <email>eliasg@infomed.sld.cu</email>
    </contact_backup>
    <investigator>
      <last_name>Nelido Gonzalez Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria University School of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayman Nabawi</last_name>
      <email>asnabawi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ayman Nabawi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayman Amin</last_name>
      <email>aymanamin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hisham Abdel Megid</last_name>
      <email>hisho83@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ayman Amin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital Bangalore</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute)</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Jain</last_name>
      <email>drsandeep740@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Harikrishnan</last_name>
      <email>hari.nhrc@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sandeep Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Subramania Iyer</last_name>
      <email>subu@aims.amrita.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kavita</last_name>
      <email>hnscoordinator@aims.amrita.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Subramania Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhashini John</last_name>
      <email>subha@cmcvellore.ac.in</email>
    </contact>
    <contact_backup>
      <last_name>Vinoth Vijay.V</last_name>
      <phone>+91 416 2282049</phone>
    </contact_backup>
    <investigator>
      <last_name>Subhashini John</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center Trivandrum, India</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Sebastian</last_name>
      <email>psebastian2091@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anju Gopan</last_name>
      <email>anjugopan2001@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Sebastian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cipto Mangunkusumo General Hospital Indonesia</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soehartati Gondhowiardjo</last_name>
      <email>soehartati@radioterapi-cm.org</email>
    </contact>
    <contact_backup>
      <last_name>Gregorious Ben Prajogi</last_name>
      <email>ben.prajogi@radioterapi-cm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Soehartati Gondhowiardjo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tak Yun</last_name>
      <email>hmotakyun@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Sangeun Lee</last_name>
      <email>piaspia@daum.net</email>
    </contact_backup>
    <investigator>
      <last_name>Tak Yun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INHA University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Mo Kim</last_name>
      <email>ymk416@inha.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>SUJIN KIM</last_name>
      <email>sj2012@inha.com</email>
    </contact_backup>
    <investigator>
      <last_name>Young-Mo Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Hwan Baek</last_name>
      <email>chbaek@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ji-Eun Lee</last_name>
      <email>ji.eun.lee@samsung.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chung-Hwan Baek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byuong Chul Cho</last_name>
      <email>cbc1971@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Sehwa Lim</last_name>
      <email>jylee1416@yuhs.ac</email>
    </contact_backup>
    <investigator>
      <last_name>Byuong Chul Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pantai Medical Centre, Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Low</last_name>
      <email>jlow@pantai.com.my</email>
    </contact>
    <contact_backup>
      <last_name>Mogana</last_name>
      <email>phkl.crc@pantai.com.my</email>
    </contact_backup>
    <investigator>
      <last_name>John Low</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mahkota Medical Center</name>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayendran K. Dharmaratnam</last_name>
      <email>navinsurfer@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tam Ling Phang</last_name>
      <email>tam@mahkotamedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jayendran K. Dharmaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mejia</last_name>
      <email>mikemejiamd@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>CHARLTON MOLINA DURAN</last_name>
      <email>chucky2276@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Mejia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Joy Calaguas</last_name>
      <email>miriamcalaguas@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Caissa Elvira Tangco</last_name>
      <email>cegtangco@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Miriam Joy Calaguas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdullah Al Amro</last_name>
      <email>aalamro@kfmc.med.sa</email>
    </contact>
    <contact_backup>
      <last_name>Doaa Abdelmoety</last_name>
      <email>dabdelmoety@kfmc.med.sa</email>
    </contact_backup>
    <investigator>
      <last_name>Abdullah Al Amro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K C Soo, Prof</last_name>
      <phone>+65 64368000</phone>
    </contact>
    <investigator>
      <last_name>K C Soo, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Centre</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Ann James</last_name>
      <email>joann@medi.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Sheila Visser</last_name>
      <email>glanders2@medi.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Jo Ann James</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GVI Oncology</name>
      <address>
        <city>Panorama</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conrad Jacobs</last_name>
      <email>Conrad.Jacobs@cancercare.co.za</email>
    </contact>
    <investigator>
      <last_name>Conrad Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ching-Yun Hsieh</last_name>
      <email>d7995@mailcmuh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Pei-Chen</last_name>
      <email>newdrug@mail.cmuh.org.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ching-Yun Hsieh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Med Univ Hosp [TMUH]</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lai-Lei Ting</last_name>
      <email>llt1957@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lai-Lei Ting</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Mu-Hsin Chang</last_name>
      <email>ptchang@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Peter Mu-Hsin Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Bangkok (+Chulabhorn for RT)</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kullathorn Thephamongkhol</last_name>
      <email>kullathorn@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kullathorn Thephamongkhol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Cuba</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase III Adjuvant Concurrent Chemo-RT +/- nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

